drugset / Trial / NCT00868114
Direct Tumor Injection KLH-Pulsed Dendritic Cells in Unresectable Pancreatic Cancer
Phase 2
Terminated
24 enrolled
Leo W. Jenkins Cancer Center
H. Lee Moffitt Cancer Center and Research Institute · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This research study uses radiation or a gene therapy agent, TNFerade in addition to a dendritic cell vaccine in patients with locally advanced or low volume metastatic pancreatic cancer. The use of TNFerade or radiation serves to generate cell death stimulating the immune response. The dendritic cell vaccine may direct a distant and lasting effective anti-tumor immune response to achieve a local and systemic clinical benefit.
Timeline
- Start
- 2006-07
- Primary completion
- 2013-07
- Completion
- 2015-12
Outcome
Outcome not reported
Stopped (Enrollment): “Poor recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | KLH-pulsed autologous dendritic cell vaccine | Vaccine | 5e+07 cells | Other |